

27 June 2016

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

cyclomedica
technegas

Cyclopharm Ltd
ABN 74 116 931 250
Bldg 75 Business & Technology Park
New Illawarra Road
Lucas Heights NSW 2234 Australia
POB 350 Menai Central NSW 2234
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Cyclopharm Signs Five Year Collaborative Agreement with the Canadian Association of Nuclear Medicine

Australian radiopharmaceutical company Cyclopharm Limited (ASX: CYC) is pleased to announce a strategic partnership with the Canadian Association of Nuclear Medicine (CANM).

The partnership is consistent with Cyclopharm's strategic objectives of:

1. Developing the United States market for Technegas, the company's proprietary superior functional lung ventilation imaging agent, following anticipated USFDA approval and;
2. Expanding the use of Technegas across the company's existing 55 established markets as well as other new markets and clinical applications to include COPD, asthma, pulmonary hypertension and lung cancer.

As part of this five year agreement, CYC will assist the CANM – through cash and in kind support – to promote state-of-the-art, appropriate and safe nuclear medicine services across Canada and to position the CANM as a major educator and contributor to the development of nuclear medicine in the rest of the world.

The CANM will work collaboratively with CYC to advocate for the use of nuclear medicine in the diagnosis and follow up of pulmonary embolism based on clinical best practices, particularly those endorsed by the European Association of Nuclear Medicine (EANM), which endorses Technegas as the best aerosol for functional lung ventilation imaging.

The CANM will also join forces with CYC to advocate for peer reviewed, validated clinical trials and evidence-based published guidelines on the use and benefits of nuclear medicine imaging in applications beyond Pulmonary Embolism such as COPD, asthma, pulmonary hypertension and lung cancer.

In line with the CANM strategic plan, the Association will collaborate with CYC in developing educational support programs that will promote clinical nuclear medicine best practice for lung ventilation/perfusion imaging across Canada and in the United States following anticipated USFDA approval for Technegas.

President of the CANM Dr Andrew Ross stated that "the Association is delighted to partner with Cyclopharm."

"Lung imaging continues to represent a major clinical tool in the field of nuclear medicine not only for the traditional use in pulmonary embolism but also with the arrival of newer technology to be

